NASDAQ:KRYSKrystal Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Krystal Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $40.12 -1.06 (-2.57 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$40.00Now: $40.12▼$42.5650-Day Range$39.91MA: $41.97▼$45.4852-Week Range$31.89Now: $40.12▼$66.85Volume149,700 shsAverage Volume172,304 shsMarket Capitalization$697.53 millionP/E RatioN/ADividend YieldN/ABeta1.01 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.80, Krystal Biotech has a potential upside of 98.9% from its current price of $40.12.Amount of Analyst CoverageKrystal Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesKrystal Biotech has received 235 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKrystal Biotech has received 234 “underperform” votes. (Add your “underperform” vote.)Community SentimentKrystal Biotech has received 50.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote “Outperform” if you believe KRYS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,175,000.00 in company stock.Percentage Held by InsidersOnly 27.40% of the stock of Krystal Biotech is held by insiders.Percentage Held by Institutions66.18% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to decrease in the coming year, from ($2.19) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -32.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -32.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS Previous Symbol CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone412-586-5830Debt Debt-to-Equity Ratio0.01 Current Ratio46.38 Quick Ratio46.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.72 per share Price / Book3.42Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-19,090,000.00 Net MarginsN/A Return on Equity-10.05% Return on Assets-9.73%Miscellaneous Employees37 Outstanding Shares17,386,000Market Cap$697.53 million Next Earnings Date11/2/2020 (Estimated) OptionableNot Optionable $40.12 -1.06 (-2.57 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KRYS News and Ratings via Email Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions How has Krystal Biotech's stock price been impacted by COVID-19? Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRYS shares have decreased by 19.6% and is now trading at $40.12. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Krystal Biotech? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Krystal Biotech. When is Krystal Biotech's next earnings date? Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Krystal Biotech. How were Krystal Biotech's earnings last quarter? Krystal Biotech Inc (NASDAQ:KRYS) posted its earnings results on Monday, August, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. View Krystal Biotech's earnings history. What price target have analysts set for KRYS? 7 brokerages have issued 12-month price objectives for Krystal Biotech's stock. Their forecasts range from $60.00 to $100.00. On average, they anticipate Krystal Biotech's share price to reach $79.80 in the next twelve months. This suggests a possible upside of 98.9% from the stock's current price. View analysts' price targets for Krystal Biotech. What are Wall Street analysts saying about Krystal Biotech stock? Here are some recent quotes from research analysts about Krystal Biotech stock: 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/8/2020) 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019) Has Krystal Biotech been receiving favorable news coverage? Headlines about KRYS stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Krystal Biotech. Are investors shorting Krystal Biotech? Krystal Biotech saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 1,490,000 shares, a decline of 12.9% from the January 31st total of 1,710,000 shares. Based on an average daily trading volume, of 156,200 shares, the short-interest ratio is currently 9.5 days. Approximately 13.7% of the company's shares are sold short. View Krystal Biotech's Short Interest. Who are some of Krystal Biotech's key competitors? Some companies that are related to Krystal Biotech include Twist Bioscience (TWST), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Legend Biotech (PCVX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Vaxart (VXRT), Cortexyme (CRTX) and Regenxbio (RGNX). View all competitors. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Pfizer (PFE), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), Fortinet (FTNT) and Inovio Pharmaceuticals (INO). Who are Krystal Biotech's key executives? Krystal Biotech's management team includes the following people: Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)Ms. Pooja Agarwal, VP of Product Devel. (Age 40)Mr. Antony A. Riley, Chief Financial Officer (Age 51)Ms. Gloria Lin, Accounting Mang. When did Krystal Biotech IPO? (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (1.64%), Victory Capital Management Inc. (1.60%), Bank of New York Mellon Corp (0.34%), Blair William & Co. IL (0.29%), Nicholas Investment Partners LP (0.23%) and Hudson Bay Capital Management LP (0.20%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan. View institutional ownership trends for Krystal Biotech. Which institutional investors are selling Krystal Biotech stock? KRYS stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Blair William & Co. IL, Alps Advisors Inc., Bank of New York Mellon Corp, Chartwell Investment Partners LLC, and Mutual of America Capital Management LLC. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan, and Suma Krishnan. View insider buying and selling activity for Krystal Biotech. Which institutional investors are buying Krystal Biotech stock? KRYS stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Goldman Sachs Group Inc., Hudson Bay Capital Management LP, SG Americas Securities LLC, Bessemer Group Inc., HighMark Wealth Management LLC, Rafferty Asset Management LLC, and Swiss National Bank. View insider buying and selling activity for Krystal Biotech. How do I buy shares of Krystal Biotech? Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $40.12. How big of a company is Krystal Biotech? Krystal Biotech has a market capitalization of $697.53 million. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe. What is Krystal Biotech's official website? The official website for Krystal Biotech is www.krystalbio.com. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
